Clinical trial
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
NCT00396591 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00396591 |
|---|---|
| Title | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites |
| Official title | A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Regeneron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
| Enrollment | 16 |
| Start date | Oct 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Nov 7, 2006 |
| Last update posted | Jan 10, 2013 |
| Countries | Italy, Sweden, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: